Marinomed Biotech AG(DE:93Z)
€3.760.00 (0.00%)
DE:93Z
Marinomed Biotech AG financials statements
€3.76
At close:0.00 (0.00%)
Marinomed Biotech AG (93Z) Ratios
1 Followers
Marinomed Biotech AG Ratios
DE:93Z's free cash flow for Q2 2024 was €0.00. For the 2024 fiscal year, DE:93Z's free cash flow was increased by €945.30K and operating cash flow was €-945.30K. See a summary of the company’s cash flow.
| Ratios | Mar 24 | Mar 23 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.74 | 2.40 | 2.14 | 2.75 | 3.81 |
| Quick Ratio | 0.63 | 2.13 | 1.97 | 2.58 | 3.79 |
| Cash Ratio | 0.27 | 1.37 | 0.96 | 1.64 | 2.99 |
| Solvency Ratio | -0.25 | -0.22 | -0.25 | -0.31 | -0.80 |
| Operating Cash Flow Ratio | -0.47 | -0.87 | -0.81 | -1.23 | -1.90 |
| Short-Term Operating Cash Flow Coverage | -0.65 | -2.13 | -6.45 | -19.30 | -135.47 |
| Net Current Asset Value | € -17.61M | € -12.18M | € -8.27M | € -2.75M | € 6.70M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.49 | 1.02 | 0.74 | 0.55 | 0.24 |
| Debt-to-Equity Ratio | -2.15 | -5.44 | 82.54 | 2.39 | 0.43 |
| Debt-to-Capital Ratio | 1.87 | 1.23 | 0.99 | 0.71 | 0.30 |
| Long-Term Debt-to-Capital Ratio | 3.15 | 1.26 | 0.99 | 0.70 | 0.29 |
| Financial Leverage Ratio | -1.44 | -5.36 | 111.48 | 4.39 | 1.79 |
| Debt Service Coverage Ratio | -0.43 | -0.65 | -1.67 | -4.55 | -8.62 |
| Interest Coverage Ratio | -3.71 | -2.29 | -2.75 | -9.75 | -9.33 |
| Debt to Market Cap | 0.49 | 0.27 | 0.12 | 0.07 | 0.03 |
| Interest Debt Per Share | 15.27 | 16.77 | 11.73 | 9.19 | 3.74 |
| Net Debt to EBITDA | -5.30 | -4.50 | -2.80 | -0.74 | 1.19 |
| Profitability Margins | |||||
| Gross Profit Margin | 12.45% | 18.98% | 12.25% | -7.90% | -8.34% |
| EBIT Margin | -46.83% | -34.43% | -35.99% | -65.15% | -106.54% |
| EBITDA Margin | -39.45% | -28.49% | -30.76% | -59.88% | -101.22% |
| Operating Profit Margin | -55.85% | -51.01% | -35.64% | -85.68% | -101.07% |
| Pretax Profit Margin | -73.95% | -56.68% | -48.97% | -73.93% | -117.37% |
| Net Profit Margin | -73.99% | -56.74% | -50.67% | -73.98% | -117.44% |
| Continuous Operations Profit Margin | -73.99% | -56.74% | -50.67% | -73.98% | -117.44% |
| Net Income Per EBT | 100.06% | 100.11% | 103.46% | 100.06% | 100.06% |
| EBT Per EBIT | 132.39% | 111.12% | 137.39% | 86.29% | 116.13% |
| Return on Assets (ROA) | -46.50% | -28.71% | -27.61% | -25.57% | -37.00% |
| Return on Equity (ROE) | 67.03% | 153.90% | -3078.00% | -112.18% | -66.41% |
| Return on Capital Employed (ROCE) | -103.44% | -35.22% | -27.05% | -38.90% | -40.13% |
| Return on Invested Capital (ROIC) | -43.05% | -34.83% | -25.75% | -38.12% | -39.78% |
| Return on Tangible Assets | -51.92% | -31.24% | -30.48% | -28.03% | -40.37% |
| Earnings Yield | -15.33% | -7.57% | -4.54% | -3.43% | -5.09% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.85 | 3.61 | 2.42 | 1.57 | 0.00 |
| Payables Turnover | 5.25 | 7.92 | 5.11 | 4.44 | 6.64 |
| Inventory Turnover | 7.94 | 5.85 | 9.93 | 9.47 | 68.28 |
| Fixed Asset Turnover | 1.54 | 1.82 | 1.81 | 1.35 | 2.47 |
| Asset Turnover | 0.63 | 0.51 | 0.54 | 0.35 | 0.32 |
| Working Capital Turnover Ratio | 3.17 | 1.49 | 1.40 | 0.77 | 1.66 |
| Cash Conversion Cycle | 71.21 | 117.49 | 116.46 | 189.16 | -49.62 |
| Days of Sales Outstanding | 94.77 | 101.15 | 151.06 | 232.87 | 0.00 |
| Days of Inventory Outstanding | 45.96 | 62.41 | 36.76 | 38.56 | 5.35 |
| Days of Payables Outstanding | 69.51 | 46.08 | 71.36 | 82.27 | 54.96 |
| Operating Cycle | 140.73 | 163.57 | 187.82 | 271.43 | 5.35 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.98 | -3.47 | -3.30 | -4.68 | -5.39 |
| Free Cash Flow Per Share | -3.07 | -3.62 | -3.92 | -7.37 | -7.04 |
| Dividend Paid and CapEx Coverage Ratio | -35.24 | -22.86 | -5.30 | -1.74 | -3.26 |
| Capital Expenditure Coverage Ratio | -35.24 | -22.86 | -5.30 | -1.74 | -3.26 |
| Operating Cash Flow Coverage Ratio | -0.21 | -0.23 | -0.31 | -0.54 | -1.65 |
| Operating Cash Flow to Sales Ratio | -0.49 | -0.46 | -0.42 | -0.85 | -1.24 |
| Free Cash Flow Yield | -10.50% | -6.42% | -4.45% | -6.20% | -7.04% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.52 | -13.21 | -22.05 | -29.13 | -19.65 |
| Price-to-Sales (P/S) Ratio | 4.83 | 7.50 | 11.17 | 21.55 | 23.08 |
| Price-to-Book (P/B) Ratio | -4.37 | -20.34 | 678.55 | 32.68 | 13.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.52 | -15.57 | -22.45 | -16.14 | -14.21 |
| Price-to-Operating Cash Flow Ratio | -9.79 | -16.25 | -26.69 | -25.43 | -18.56 |
| Price-to-Earnings Growth (PEG) Ratio | -1.33 | -1.88 | 9.02 | 1.48 | 0.57 |
| Enterprise Value Multiple | -17.54 | -30.81 | -39.11 | -36.73 | -21.61 |
| Enterprise Value | 63.54M | 98.99M | 139.87M | 178.69M | 134.43M |
| EV to EBITDA | -17.54 | -30.81 | -39.11 | -36.73 | -21.61 |
| EV to Sales | 6.92 | 8.78 | 12.03 | 21.99 | 21.88 |
| EV to Free Cash Flow | -13.64 | -18.23 | -24.18 | -16.47 | -13.47 |
| EV to Operating Cash Flow | -14.03 | -19.03 | -28.74 | -25.95 | -17.59 |
| Tangible Book Value Per Share | -7.68 | -3.98 | -1.23 | 2.24 | 6.52 |
| Shareholders’ Equity Per Share | -6.68 | -2.77 | 0.13 | 3.64 | 7.66 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.03 | -0.00 | -0.00 |
| Revenue Per Share | 6.05 | 7.52 | 7.88 | 5.52 | 4.33 |
| Net Income Per Share | -4.48 | -4.27 | -3.99 | -4.09 | -5.09 |
| Tax Burden | 1.00 | 1.00 | 1.03 | 1.00 | 1.00 |
| Interest Burden | 1.58 | 1.65 | 1.36 | 1.13 | 1.10 |
| Research & Development to Revenue | 0.00 | 0.61 | 0.65 | 0.73 | 0.78 |
| SG&A to Revenue | 0.11 | 0.12 | 0.09 | 0.13 | 0.19 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.67 | 0.81 | 0.83 | 1.15 | 1.06 |
Currency in EUR

